These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21142763)

  • 21. National Institutes of Health. A government niche for translational medicine and drug development.
    Kaiser J
    Science; 2010 Dec; 330(6010):1462-3. PubMed ID: 21148358
    [No Abstract]   [Full Text] [Related]  

  • 22. Federal funding in support of Ebola medical countermeasures R&D.
    Boddie C
    Health Secur; 2015; 13(1):3-8. PubMed ID: 25812423
    [No Abstract]   [Full Text] [Related]  

  • 23. Leveraging public private partnerships to innovate under challenging budget times.
    Portilla LM; Rohrbaugh ML
    Curr Top Med Chem; 2014; 14(3):326-9. PubMed ID: 24283971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Public-private partnerships to revitalize psychiatric drug discovery.
    Brady LS; Potter WZ
    Expert Opin Drug Discov; 2014 Jan; 9(1):1-8. PubMed ID: 24308355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
    Outterson K; McDonnell A
    Health Aff (Millwood); 2016 May; 35(5):784-90. PubMed ID: 27140983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.
    Kostyanev T; Bonten MJ; O'Brien S; Steel H; Ross S; François B; Tacconelli E; Winterhalter M; Stavenger RA; Karlén A; Harbarth S; Hackett J; Jafri HS; Vuong C; MacGowan A; Witschi A; Angyalosi G; Elborn JS; deWinter R; Goossens H
    J Antimicrob Chemother; 2016 Feb; 71(2):290-5. PubMed ID: 26568581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biodefense. Critics question proposed countermeasures agency.
    Kaiser J
    Science; 2005 Nov; 310(5749):755. PubMed ID: 16272086
    [No Abstract]   [Full Text] [Related]  

  • 28. Funding medical and health-related research in the public interest.
    Baird PA
    CMAJ; 1996 Aug; 155(3):299-301. PubMed ID: 8705910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microbiology. Détente declared on NIH biodefense funding.
    Kaiser J
    Science; 2005 May; 308(5724):938. PubMed ID: 15890854
    [No Abstract]   [Full Text] [Related]  

  • 30. [French biomedical competitiveness clusters: opportunities for public-private partnerships].
    Vasmant D
    Bull Acad Natl Med; 2009 Dec; 193(9):2035-43; discussion 2044. PubMed ID: 20666016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Federal agency biodefense funding, FY2013-FY2014.
    Sell TK; Watson M
    Biosecur Bioterror; 2013 Sep; 11(3):196-216. PubMed ID: 23906009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare.
    Wellenreuther R; Keppler D; Mumberg D; Ziegelbauer K; Lessl M
    Drug Discov Today; 2012 Nov; 17(21-22):1242-8. PubMed ID: 22521665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of public private partnerships in highways.
    Hakim S; Meehan B
    Eval Program Plann; 2024 Dec; 107():102490. PubMed ID: 39216425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The NHLBI-UnitedHealth Global Health Centers of Excellence Program: Assessment of Impact of Federal Funding Through a Social Network Analysis.
    Dianis NL; Wolbach TL; Spiegelman M
    Glob Heart; 2016 Mar; 11(1):145-148.e1. PubMed ID: 27102034
    [No Abstract]   [Full Text] [Related]  

  • 35. Billions for biodefense: federal agency biodefense funding, FY2007-FY2008.
    Franco C; Deitch S
    Biosecur Bioterror; 2007 Jun; 5(2):117-33. PubMed ID: 17608598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biodefense. Has biodefense gone overboard?
    Enserink M; Kaiser J
    Science; 2005 Mar; 307(5714):1396-8. PubMed ID: 15746402
    [No Abstract]   [Full Text] [Related]  

  • 38. Biodefense: spend, but spend wisely.
    Green SK; Morin K
    Am J Bioeth; 2005; 5(4):50-2. PubMed ID: 16109698
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug discovery: new models for industry-academic partnerships.
    Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
    Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Billions for biodefense: federal agency biodefense funding, FY2008-FY2009.
    Franco C
    Biosecur Bioterror; 2008 Jun; 6(2):131-46. PubMed ID: 18582165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.